RNautophagy is a newly-described type of selective autophagy whereby cellular RNAs are transported into lysosomes for degradation. This process involves the transmembrane protein SIDT2, which transports double-stranded RNA (dsRNA) across the endolysosomal membrane. We previously demonstrated that SIDT2 is a transcriptional target of p53, but its role in tumorigenesis -if any -is unclear. Unexpectedly, we show here that Sidt2 -/mice with concurrent oncogenic Kras G12D activation develop significantly fewer tumors than littermate controls in a mouse model of lung adenocarcinoma (LUAD). Consistent with this observation, loss of SIDT2 also leads to enhanced survival and delayed tumor development in an Apc min/+ mouse model of intestinal cancer. Within the intestine, Apc min/+ ;Sidt2 -/mice display accumulation of dsRNA in association with increased phosphorylation of eIF2α and JNK as well as elevated rates of apoptosis. Taken together, our data demonstrate a role for SIDT2 -and by extension RNautophagy -in promoting tumor development.
INTRODUCTION
The C. elegans double-stranded RNA transporter (dsRNA) SID-1 is conserved throughout much of animal evolution, and mammals possess two paralogs, SIDT1 and SIDT2 1, 2 . SIDT2 is broadly expressed in mammalian tissue and localizes within late endosomes and lysosomes 3, 4 . Human and mouse Sidt2 homologues show 95% sequence identity across the entire protein (832 amino acids) and 100% identity at the C-terminal 100 amino acids 4 . Such a high degree of conservation implies a strongly-selected function, and studies have recently emerged that shed light on the role of SIDT2 in mammals.
On the one hand, SIDT2 appears to have retained RNA transporter activity. This was initially suggested by the observation that the ectodomain of SIDT2 binds long dsRNA in vitro, similar to C. elegans SID-1 5 . Consistent with this finding, we subsequently discovered that SIDT2 transports viral dsRNA and that this transport is important for anti-viral immunity 4 .
More specifically, we found that SIDT2 promotes the trafficking of internalized dsRNA across the endo-lysosomal membrane and into the cytoplasm, where it is recognized by RNA sensors, which in turn promote anti-viral, type I interferon (IFN) signaling. Loss of SIDT2 thus impairs IFN production and survival after viral infection is significantly reduced 4 . In parallel, SIDT2 has also recently been reported to traffic RNAs into the lysosome for degradation in a novel process described as "RNautophagy" 6 . These experimentsperformed using cell-free biochemical assays -suggested that SIDT2 promotes destruction of endogenous RNAs by transporting them from the cytosol into lysosomes. Such transport would thus be in the opposite direction to that described for viral RNAs, but is potentially consistent with previous observations that RNA transport by C. elegans SID-1 is bidirectional and dependent on RNA concentration 1 .
On the other hand, some studies have observed physiological effects of SIDT2 where the relationship to RNA transport -if any -is unclear. For example, mice lacking SIDT2 demonstrate impaired glucose tolerance, decreased serum insulin levels, and defective insulin secretion [7] [8] [9] . Two recent studies also demonstrated that Sidt2 -/mice develop non-alcoholic fatty liver disease (NAFLD) 10, 11 , with one suggesting that this is due to induction of endoplasmic reticulum stress 10 and the other proposing that it is the result of defective autophagy 11 . Finally, work from our group has also demonstrated a potential role for SIDT2 in tumorigenesis 12 . Specifically, we found that SIDT2 is a transcriptional target of the tumor suppressor p53, that SIDT2 overexpression in HrasV12;p53 null mouse embryo fibroblasts (MEFs) impairs cell proliferation, and that shRNA-mediated knockdown of Sidt2 in a fibrosarcoma model leads to increased tumor growth following transplantation into immunocompromised Scid mice 12 . Together with the observation that SIDT2 is transcriptionally downregulated in patient tumors compared to healthy tissue 13 , these findings thus support a possible tumor suppressive role for SIDT2.
In the current study, we further investigated the role of SIDT2 in tumor development.
Unexpectedly, we found that mice lacking SIDT2 display reduced tumor burden and increased survival in both lung adenocarcinoma (LUAD) and intestinal cancer models.
Moreover, consistent with its role in dsRNA transport, loss of SIDT2 leads to accumulation of dsRNA, resulting in increased phosphorylation of eIF2α and elevated rates of apoptosis.
Our findings therefore suggest that SIDT2 -and by extension RNautophagy -play a role in promoting tumor development.
RESULTS

Loss of SIDT2 inhibits lung adenocarcinoma development
Given the finding that Sidt2 is a p53 target gene, we sought to investigate its role in tumor suppression in vivo. Lung cancer is the leading cause of cancer deaths worldwide, and loss or mutation of p53 is common in this tumor type. Therefore, we examined the role of Sidt2 in LUAD tumorigenesis by employing an autochthonous mouse model in which mice conditionally express oncogenic Kras G12D under the control of a lox-STOP-lox element (Kras LSL-G12D ). Intratracheal inoculation of adenoviral Cre recombinase excises the STOP cassette, resulting in expression of Kras G12D specifically in lung cells. Kras G12D expression drives development of non-small cell lung tumors, and loss of p53 promotes tumor progression in this model 14 . To assess the role of SIDT2 in tumorigenesis in this LUAD model, we crossed Sidt2 -/mice previously generated in our lab 4 with Kras LSL-G12D/+ mice, and subsequently assessed lung tumor burden in Kras LSL-G12D/+ ;Sidt2 +/+ and Kras LSL-G12D/+ ;Sidt2 -/mice eighteen weeks after intratracheal adenoviral inoculation. In contrast to our previous report suggesting that SIDT2 has a tumor suppressive role in fibrosarcoma, light microscopic analysis of H&E-stained lung sections showed that Sidt2 -/animals have reduced tumor burden ( Figure 1A ). This was confirmed with subsequent quantification, which showed that mice deficient in SIDT2 developed significantly fewer tumors ( Figure 1B ) and had a significant reduction in overall tumor burden ( Figure 1C ). Next, we wanted to investigate whether the loss of SIDT2 leads to an impairment of cellular proliferation. To do so, we compared expression of Ki67, a cellular marker of proliferation, using immunohistochemical staining ( Figure 1D ). Consistent with an impairment in cellular proliferation, tumors from Kras LSL-G12D/+ ;Sidt2 -/mice had significantly less Ki67-positive cells compared to controls ( Figure 1E ). Together, these results thus suggest that SIDT2 facilitates tumor development in the Kras G12D LUAD model.
Loss of SIDT2 inhibits growth of Apc min intestinal tumors
The difference in the role for SIDT2 in tumorigenesis in the mouse fibrosarcoma and LUAD models prompted us to test another mouse tumor model to examine for context-dependency of Sidt2 in cancer. To this end, we chose the well characterized Apc min mouse model of intestinal cancer. These mice harbor a dominant mutation in the oncogenic Apc gene which leads to spontaneous development of adenomatous polyps, primarily in the distal small intestine (DSI) 15, 16 .
We subsequently generated Apc min/+ mice lacking Sidt2 ( Figure S1 ) and monitored the animals over time, sacrificing them after the onset of anemia and/or signs of ill health associated with death in this model (e.g. hunching of the back, weight loss). Apc min/+ ;Sidt2 -/mice (median survival: 131 days) survived significantly longer than both Apc min/+ ;Sidt2 +/+ and Apc min/+ ;Sidt2 +/mice (median survival: 93 and 99 days respectively), suggesting that loss of SIDT2 impairs intestinal tumor development ( Figure 2A ). To investigate further, Apc min/+ ;Sidt2 -/mice were sacrificed at day 100 and appeared to have a lower tumor burden within the DSI compared to Apc min/+ ;Sidt2 +/+ mice ( Figure 2B ). To properly assess this, tumor number ( Figure 2C -E) and tumor area ( Figure 2G -I) were calculated in the distal (DSI), medial (MSI) and proximal (PSI) small intestine of 100-day old Apc min/+ ;Sidt2 +/+ and Apc min/+ ;Sidt2 -/mice. While there was no difference in tumor number in the colon ( Figure   S2A ) or PSI, Apc min/+ ;Sidt2 -/mice had significantly fewer tumors than Apc min/+ ;Sidt2 +/+ mice in the MSI and DSI. Moreover, Apc min/+ ;Sidt2 -/mice also had smaller tumors than Apc min/+ ;Sidt2 +/+ mice in the DSI, MSI and PSI, but again showed no difference in the colon, where tumors are uncommon ( Figure S2B ). Together, these results suggest that SIDT2 also facilitates tumor development in the Apc min mouse model of intestinal cancer.
Since Apc min/+ ;Sidt2 -/mice had significantly smaller tumors than Apc min/+ ;Sidt2 +/+ mice across all segments of the small intestine ( Figure 2G -I), we hypothesized that loss of SIDT2 does not affect tumor initiation, but instead plays a role in the growth of tumors by impairing cell proliferation. To investigate this possibility, we compared expression of Ki67 in tumors of Apc min/+ ;Sidt2 -/and Apc min/+ ;Sidt2 +/+ mice ( Figure 3A) . Consistent with the decrease in Ki67-positive cells observed in Kras LSL-G12D/+ ;Sidt2 -/mice, Apc min/+ ;Sidt2 -/mice had significantly less Ki67 positive staining overall ( Figure 3B ), as well as fewer intratumoral Ki67-positive cells ( Figure 3C ) compared to Apc min/+ ;Sidt2 +/+ mice.
SIDT2 is required to prevent dsRNA accumulation and PKR/eIF2α pathway activation
Given the role of SIDT2 in transporting dsRNA across the endo-lysosomal membrane 4 , we next assessed the effect of SIDT2 on the subcellular localisation of dsRNA within the DSI.
To do so, we performed immunofluorescence staining on frozen sections of the DSI of 100day old Apc min/+ ;Sidt2 -/and Apc min/+ ;Sidt2 +/+ mice using the J2 monoclonal antibody ( Figure   4A ), which specifically detects dsRNA helices at least 40bp in length, in a sequenceindependent manner 17 . Notably, staining for dsRNA was readily observed within the intestinal crypts of Apc min/+ ;Sidt2 -/mice but was absent in crypts of Apc min/+ ;Sidt2 +/+ animals and in other parts of the DSI, including tumors ( Figure 4B ). To confirm that this was not specific to the Apc min/+ mouse model, we also performed dsRNA staining in lungs of Kras LSL-G12D/+ ; Sidt2 +/+ and Kras LSL-G12D/+ ; Sidt2 -/mice using immunohistochemistry ( Figure S3A ).
Consistent with our previous data, we observed a significant increase in cytosolic dsRNA staining in Kras LSL-G12D/+ ; Sidt2 -/mice compared to controls ( Figure S3B ) suggesting that loss of SIDT2 leads to accumulation of dsRNA in the cytosol.
Cytosolic dsRNAs are bound by RNA-dependent protein kinase (PKR), leading to its autophosphorylation and activation 18 . Activated PKR subsequently phosphorylates the α subunit of protein synthesis initiation factor eIF2 (eIF2α), resulting in inhibition of protein translation as well as anti-viral and anti-tumor effects (10, 11) . We therefore wished to determine whether the accumulation of dsRNA in cells deficient for SIDT2 was likely to activate PKR.
Although we tested multiple antibodies raised against phosphorylated PKR, none showed an ability to recognize activated murine PKR in control samples via western blot (data not shown), so instead we compared phosphorylation of eIF2α as a proxy for PKR activation.
Moreover, since we only observed SIDT2-dependent dsRNA accumulation in the intestinal crypts and not in tumors themselves, we analyzed p-eIF2α expression separately in nontumor and tumor tissue from the DSI of Apc min/+ ;Sidt2 -/and Apc min/+ ;Sidt2 +/+ mice. Notably, Apc min/+ ;Sidt2 +/+ mice displayed higher p-eIF2α levels in non-tumor tissue ( Figure 4C ), consistent with dsRNA accumulation and activation of PKR within these cells. This SIDT2dependent increase in p-eIF2α was less apparent in tumor tissue ( Figure 4D ).
In addition to its role in the inhibition of protein translation, PKR activation has been shown to mediate cellular stress responses via regulation of mitogen-activated protein kinases However, consistent with a context-dependent role, intratumoral SIDT2 RNA levels showed no prognostic significance in 10 other cancers (including LUAD and colon cancer), and lower intratumoral SIDT2 levels were actually associated with poorer survival in pancreatic and cervical cancers ( Figure S5 ).
DISCUSSION
In this study, we show that the mammalian SID-1 ortholog SIDT2, which is a transcriptional target for p53, promotes tumor growth. Specifically, loss of SIDT2 in mice caused reduced tumor burden and enhanced survival, with the latter observation supported by data from patients with several different cancers in which lower SIDT2 expression was associated with an improved prognosis.
Mechanistically, our data from Apc min animals suggest a model in which the absence of Although we were unable to directly test PKR activation due to a lack of suitable reagents, PKR nonetheless seems a likely candidate in mediating the downstream effects in our Apc min Sidt2 -/mice. After all, PKR has well-established roles not only in binding and responding to intracellular dsRNA, but also inducing eIF2α phosphorylation, JNK activation and caspase 8mediated activation of caspase 3 to induce apoptosis. Consistent with our results, PKR expression and auto-phosphorylation has previously been reported to be increased in multiple human malignancies, including colon and lung cancer 26,27 , and those with higher p-PKR and p-eIF2α had significantly longer survival [28] [29] [30] .
Given the presence of intracellular dsRNA in Apc min ;Sidt2 -/intestinal crypts, we also assessed whether there was induction of a type I interferon (IFN) response in these tissues.
However, we were unable to detect upregulation of Ifnβ or various IFN stimulated genes in tissues of Apc min/+ ;Sidt2 -/mice (data not shown), suggesting that the reduced tumor burden observed in SIDT2-deficient mice is unlikely to be due to the anti-tumor effects of type I IFN 31 . This lack of a type I IFN response may also provide a clue as to the nature of the dsRNA that accumulates in the absence of SIDT2. Specifically, the type I IFN response to cytoplasmic dsRNA is mainly orchestrated by the RIG-I-like receptors (RLRs), RIG-I and MDA-5 32, 33 . RIG-I specifically recognizes short dsRNA and ssRNA with 5' triphosphate ends 34, 35 -a common feature of viral RNAs -and MDA-5 is critical for the detection of long dsRNAs (>1000 bp) [36] [37] [38] 46 . These RNA species may therefore be more likely to accumulate in the absence of SIDT2. At the same time, it has been proposed that autophagy is important for the degradation of many types of cytosolic RNAs, including retrotransposon, viral and cellular messenger RNAs 6,47,48 so impaired lysosomal degradation of RNA in the absence of SIDT2 could also lead to accumulation of these RNAs within the intestinal crypt. Future studies to identify the RNA cargo of SIDT2 within the intestine will clarify these possibilities.
Finally, it should be noted that the apparent protective effect of lower intratumoral SIDT2 levels on patient survival was limited to certain types of cancers. Moreover, in pancreatic and cervical cancers, lower intratumoral SIDT2 levels were associated with poorer survival.
Thus, the role of SIDT2 in promoting tumor growth may only apply in specific contexts, and this may explain the apparent contradiction between the data described here and our earlier findings, which found that SIDT2 functions as a tumor suppressor in a fibrosarcoma model 12 . Regardless, the results from this study identify a role for SIDT2 and RNautophagy in promoting cancer development in vivo, and suggest the possibility that strategies to inhibit SIDT2 and/or RNautophagy could be a useful adjunct to existing treatment for certain types of cancer. 
Analysis of Kras LSL-G12D/+ LUAD mouse model
Kras LSL-G12D/+ ;Sidt2 -/and Kras LSL-G12D/+ ;Sidt2 +/+ aged 6-8 weeks were inoculated with 4x10 6 PFU Adenovirus containing Cre recombinase (University of Iowa Viral Vector Core) by intra-tracheal intubation 14 . Eighteen weeks after inoculation, the lungs were harvested, fixed in 10% formalin, and bread-loafed into approximately 12 pieces per lung. The pieces were sectioned, stained with hematoxylin and eosin (H&E) as described below, and analyzed for tumor number and tumor burden.
Histological analyses
For histological examination of the intestine, colon, distal, medial and proximal portions of 
Immunofluorescence staining of dsRNA
Frozen sections were fixed in 4% paraformaldehyde for 10 min on ice and washed 3 times in cold PBS permeabilized using 0.1% Tween/PBS, blocked in 5% normal goat serum for 1 h and stained with J2 (SciCon) primary antibody (1:200) overnight. Slides were subsequently washed 3 times for 5 min in PBS and then incubated with anti-mouse Alexa-594 secondary antibody for 1 h at room temperature. Sections were washed 3 times for 5 min in PBS and then cover-slipped and mounted using Fluoroshield mounting medium with DAPI (Sigma Aldrich). Stained sections were imaged on a Zeiss Axio Observer wide-field fluorescence microscope.
Western blotting
Intestinal tumor and adjacent non-tumor tissue were lysed in KALB lysis buffer supplemented with protease inhibitor and phosphatase inhibitor (Roche) and then homogenized using a QIAGEN TissueLyser II, according to manufacturer's instructions. 
